Ageing  ||| S:0 E:7 ||| NNP
and  ||| S:7 E:11 ||| CC
changes  ||| S:11 E:19 ||| NNS
in  ||| S:19 E:22 ||| IN
phosphate  ||| S:22 E:32 ||| JJ
transport ||| S:32 E:41 ||| NN
:  ||| S:41 E:43 ||| :
clinical  ||| S:43 E:52 ||| JJ
implications  ||| S:52 E:65 ||| NNS
Hyperphosphatemia  ||| S:65 E:83 ||| NNP
is  ||| S:83 E:86 ||| VBZ
pivotal  ||| S:86 E:94 ||| VBN
in  ||| S:94 E:97 ||| IN
some  ||| S:97 E:102 ||| DT
complications  ||| S:102 E:116 ||| JJ
secondary  ||| S:116 E:126 ||| JJ
to  ||| S:126 E:129 ||| TO
kidney  ||| S:129 E:136 ||| NN
dysfunction ||| S:136 E:147 ||| NN
.  ||| S:147 E:149 ||| .
Current  ||| S:149 E:157 ||| JJ
guidelines  ||| S:157 E:168 ||| NNS
suggest  ||| S:168 E:176 ||| VBP
that  ||| S:176 E:181 ||| IN
hyperphosphatemia  ||| S:181 E:199 ||| JJ
secondary  ||| S:199 E:209 ||| JJ
to  ||| S:209 E:212 ||| TO
kidney  ||| S:212 E:219 ||| NN
dysfunction  ||| S:219 E:231 ||| NN
develops  ||| S:231 E:240 ||| VBZ
only  ||| S:240 E:245 ||| RB
when  ||| S:245 E:250 ||| WRB
glomerular  ||| S:250 E:261 ||| JJ
filtration  ||| S:261 E:272 ||| JJ
rate  ||| S:272 E:277 ||| NN
is  ||| S:277 E:280 ||| VBZ
reduced  ||| S:280 E:288 ||| VBN
well  ||| S:288 E:293 ||| RB
below  ||| S:293 E:299 ||| IN
the  ||| S:299 E:303 ||| DT
threshold  ||| S:303 E:313 ||| NN
of  ||| S:313 E:316 ||| IN
60  ||| S:316 E:319 ||| CD
ml ||| S:319 E:321 ||| CD
/ ||| S:321 E:322 ||| CD
min ||| S:322 E:325 ||| NNS
.  ||| S:325 E:327 ||| .
This  ||| S:327 E:332 ||| DT
paper  ||| S:332 E:338 ||| NN
deals  ||| S:338 E:344 ||| NNS
with  ||| S:344 E:349 ||| IN
the  ||| S:349 E:353 ||| DT
relationship  ||| S:353 E:366 ||| NN
of  ||| S:366 E:369 ||| IN
age  ||| S:369 E:373 ||| NN
with  ||| S:373 E:378 ||| IN
serum  ||| S:378 E:384 ||| JJ
phosphorus  ||| S:384 E:395 ||| NN
and  ||| S:395 E:399 ||| CC
with  ||| S:399 E:404 ||| IN
the  ||| S:404 E:408 ||| DT
possible  ||| S:408 E:417 ||| JJ
influences  ||| S:417 E:428 ||| NNS
of  ||| S:428 E:431 ||| IN
this  ||| S:431 E:436 ||| DT
relationship  ||| S:436 E:449 ||| NN
on  ||| S:449 E:452 ||| IN
hyperphosphatemia  ||| S:452 E:470 ||| JJ
secondary  ||| S:470 E:480 ||| JJ
to  ||| S:480 E:483 ||| TO
kidney  ||| S:483 E:490 ||| NN
dysfunction ||| S:490 E:501 ||| NN
.  ||| S:501 E:503 ||| .
A  ||| S:503 E:505 ||| DT
recent  ||| S:505 E:512 ||| JJ
epidemiologic  ||| S:512 E:526 ||| JJ
study  ||| S:526 E:532 ||| NN
shows  ||| S:532 E:538 ||| NNS
that  ||| S:538 E:543 ||| IN
serum  ||| S:543 E:549 ||| JJ
phosphorus  ||| S:549 E:560 ||| JJ
decreases  ||| S:560 E:570 ||| NNS
over  ||| S:570 E:575 ||| IN
time  ||| S:575 E:580 ||| NN
not  ||| S:580 E:584 ||| RB
only  ||| S:584 E:589 ||| RB
in  ||| S:589 E:592 ||| IN
pediatric  ||| S:592 E:602 ||| JJ
age  ||| S:602 E:606 ||| NN
but  ||| S:606 E:610 ||| CC
also  ||| S:610 E:615 ||| RB
during  ||| S:615 E:622 ||| IN
adulthood ||| S:622 E:631 ||| NN
.  ||| S:631 E:633 ||| .
This  ||| S:633 E:638 ||| DT
decrease  ||| S:638 E:647 ||| NN
differs  ||| S:647 E:655 ||| VBZ
between  ||| S:655 E:663 ||| IN
men  ||| S:663 E:667 ||| NNS
and  ||| S:667 E:671 ||| CC
women ||| S:671 E:676 ||| NNS
:  ||| S:676 E:678 ||| :
continuous  ||| S:678 E:689 ||| JJ
in  ||| S:689 E:692 ||| IN
men ||| S:692 E:695 ||| NNS
,  ||| S:695 E:697 ||| ,
but  ||| S:697 E:701 ||| CC
not  ||| S:701 E:705 ||| RB
in  ||| S:705 E:708 ||| IN
women ||| S:708 E:713 ||| NNS
,  ||| S:713 E:715 ||| ,
because  ||| S:715 E:723 ||| IN
of  ||| S:723 E:726 ||| IN
a  ||| S:726 E:728 ||| DT
transitory  ||| S:728 E:739 ||| JJ
serum  ||| S:739 E:745 ||| JJ
phosphorus  ||| S:745 E:756 ||| JJ
increase  ||| S:756 E:765 ||| NN
during  ||| S:765 E:772 ||| IN
climacterics ||| S:772 E:784 ||| NN
.  ||| S:784 E:786 ||| .
Data  ||| S:786 E:791 ||| NNS
show  ||| S:791 E:796 ||| VBP
also  ||| S:796 E:801 ||| RB
that  ||| S:801 E:806 ||| IN
age-associated  ||| S:806 E:821 ||| JJ
differences  ||| S:821 E:833 ||| NNS
in  ||| S:833 E:836 ||| IN
serum  ||| S:836 E:842 ||| JJ
phosphorus  ||| S:842 E:853 ||| NN
among  ||| S:853 E:859 ||| IN
adults  ||| S:859 E:866 ||| NNS
are  ||| S:866 E:870 ||| VBP
explained  ||| S:870 E:880 ||| VBN
by  ||| S:880 E:883 ||| IN
differences  ||| S:883 E:895 ||| NNS
in  ||| S:895 E:898 ||| IN
the  ||| S:898 E:902 ||| DT
maximal  ||| S:902 E:910 ||| JJ
phosphorus  ||| S:910 E:921 ||| JJ
reabsorption  ||| S:921 E:934 ||| NN
in  ||| S:934 E:937 ||| IN
the  ||| S:937 E:941 ||| DT
renal  ||| S:941 E:947 ||| JJ
proximal  ||| S:947 E:956 ||| JJ
tubule  ||| S:956 E:963 ||| NNS
( ||| S:963 E:964 ||| -LRB-
TmP ||| S:964 E:967 ||| NNP
/ ||| S:967 E:968 ||| NNP
GFR ||| S:968 E:971 ||| NNP
) ||| S:971 E:972 ||| -RRB-
.  ||| S:972 E:974 ||| .
Other  ||| S:974 E:980 ||| JJ
studies  ||| S:980 E:988 ||| NNS
suggest  ||| S:988 E:996 ||| VBP
that  ||| S:996 E:1001 ||| IN
the  ||| S:1001 E:1005 ||| DT
opposite  ||| S:1005 E:1014 ||| JJ
influences  ||| S:1014 E:1025 ||| NNS
on  ||| S:1025 E:1028 ||| IN
TmP ||| S:1028 E:1031 ||| NNP
/ ||| S:1031 E:1032 ||| NNP
GFR  ||| S:1032 E:1036 ||| NNP
of  ||| S:1036 E:1039 ||| IN
growth  ||| S:1039 E:1046 ||| NN
hormone  ||| S:1046 E:1054 ||| NN
( ||| S:1054 E:1055 ||| -LRB-
stimulation ||| S:1055 E:1066 ||| LS
)  ||| S:1066 E:1068 ||| -RRB-
and  ||| S:1068 E:1072 ||| CC
estrogen  ||| S:1072 E:1081 ||| NNS
( ||| S:1081 E:1082 ||| -LRB-
inhibition ||| S:1082 E:1092 ||| LS
)  ||| S:1092 E:1094 ||| -RRB-
are  ||| S:1094 E:1098 ||| VBP
the  ||| S:1098 E:1102 ||| DT
determinants  ||| S:1102 E:1115 ||| NN
of  ||| S:1115 E:1118 ||| IN
the  ||| S:1118 E:1122 ||| DT
age-associated  ||| S:1122 E:1137 ||| JJ
changes  ||| S:1137 E:1145 ||| NNS
in  ||| S:1145 E:1148 ||| IN
TmP ||| S:1148 E:1151 ||| NNP
/ ||| S:1151 E:1152 ||| NNP
GFR  ||| S:1152 E:1156 ||| NNP
and  ||| S:1156 E:1160 ||| CC
serum  ||| S:1160 E:1166 ||| JJ
phosphorus ||| S:1166 E:1176 ||| NN
.  ||| S:1176 E:1178 ||| .
The  ||| S:1178 E:1182 ||| DT
decline  ||| S:1182 E:1190 ||| NN
of  ||| S:1190 E:1193 ||| IN
serum  ||| S:1193 E:1199 ||| JJ
phosphorus  ||| S:1199 E:1210 ||| NN
with  ||| S:1210 E:1215 ||| IN
age  ||| S:1215 E:1219 ||| NN
leads  ||| S:1219 E:1225 ||| VBZ
to  ||| S:1225 E:1228 ||| TO
the  ||| S:1228 E:1232 ||| DT
hypothesis  ||| S:1232 E:1243 ||| NN
that ||| S:1243 E:1247 ||| IN
,  ||| S:1247 E:1249 ||| ,
in  ||| S:1249 E:1252 ||| IN
the  ||| S:1252 E:1256 ||| DT
presence  ||| S:1256 E:1265 ||| NN
of  ||| S:1265 E:1268 ||| IN
a  ||| S:1268 E:1270 ||| DT
disorder  ||| S:1270 E:1279 ||| NN
inducing  ||| S:1279 E:1288 ||| VBG
phosphorus  ||| S:1288 E:1299 ||| JJ
retention ||| S:1299 E:1308 ||| NN
,  ||| S:1308 E:1310 ||| ,
the  ||| S:1310 E:1314 ||| DT
prevalence  ||| S:1314 E:1325 ||| NN
of  ||| S:1325 E:1328 ||| IN
hyperphosphatemia  ||| S:1328 E:1346 ||| NNS
should  ||| S:1346 E:1353 ||| MD
be  ||| S:1353 E:1356 ||| VB
higher  ||| S:1356 E:1363 ||| JJR
in  ||| S:1363 E:1366 ||| IN
young  ||| S:1366 E:1372 ||| JJ
adults  ||| S:1372 E:1379 ||| NNS
than  ||| S:1379 E:1384 ||| IN
in  ||| S:1384 E:1387 ||| IN
the  ||| S:1387 E:1391 ||| DT
elderly  ||| S:1391 E:1399 ||| JJ
because  ||| S:1399 E:1407 ||| IN
the  ||| S:1407 E:1411 ||| DT
healthy  ||| S:1411 E:1419 ||| JJ
elderly  ||| S:1419 E:1427 ||| NNS
have  ||| S:1427 E:1432 ||| VBP
lower  ||| S:1432 E:1438 ||| RBR
serum  ||| S:1438 E:1444 ||| JJ
phosphorus ||| S:1444 E:1454 ||| NN
.  ||| S:1454 E:1456 ||| .
A  ||| S:1456 E:1458 ||| DT
large  ||| S:1458 E:1464 ||| JJ
clinical  ||| S:1464 E:1473 ||| JJ
study  ||| S:1473 E:1479 ||| NN
supports  ||| S:1479 E:1488 ||| VBZ
this  ||| S:1488 E:1493 ||| DT
hypothesis  ||| S:1493 E:1504 ||| JJ
showing  ||| S:1504 E:1512 ||| NN
that  ||| S:1512 E:1517 ||| IN
hyperphosphatemia  ||| S:1517 E:1535 ||| JJ
secondary  ||| S:1535 E:1545 ||| JJ
to  ||| S:1545 E:1548 ||| TO
kidney  ||| S:1548 E:1555 ||| NN
dysfunction  ||| S:1555 E:1567 ||| NN
is  ||| S:1567 E:1570 ||| VBZ
approximately  ||| S:1570 E:1584 ||| RB
4  ||| S:1584 E:1586 ||| CD
times  ||| S:1586 E:1592 ||| NNS
higher  ||| S:1592 E:1599 ||| JJR
at  ||| S:1599 E:1602 ||| IN
age  ||| S:1602 E:1606 ||| NN
< ||| S:1606 E:1607 ||| SYM
65  ||| S:1607 E:1610 ||| CD
that  ||| S:1610 E:1615 ||| IN
at  ||| S:1615 E:1618 ||| IN
age  ||| S:1618 E:1622 ||| NN
> ||| S:1622 E:1623 ||| CD
65 ||| S:1623 E:1625 ||| CD
.  ||| S:1625 E:1627 ||| .
Data  ||| S:1627 E:1632 ||| NNS
suggest  ||| S:1632 E:1640 ||| VBP
that  ||| S:1640 E:1645 ||| IN
the  ||| S:1645 E:1649 ||| DT
relation  ||| S:1649 E:1658 ||| NN
between  ||| S:1658 E:1666 ||| IN
kidney  ||| S:1666 E:1673 ||| NN
function  ||| S:1673 E:1682 ||| NN
and  ||| S:1682 E:1686 ||| CC
serum  ||| S:1686 E:1692 ||| JJ
phosphorus  ||| S:1692 E:1703 ||| NN
should  ||| S:1703 E:1710 ||| MD
be  ||| S:1710 E:1713 ||| VB
reevaluated  ||| S:1713 E:1725 ||| VBN
considering  ||| S:1725 E:1737 ||| VBG
the  ||| S:1737 E:1741 ||| DT
possible  ||| S:1741 E:1750 ||| JJ
confounding  ||| S:1750 E:1762 ||| JJ
effect  ||| S:1762 E:1769 ||| NN
of  ||| S:1769 E:1772 ||| IN
age ||| S:1772 E:1775 ||| NN
.  ||| S:1775 E:1777 ||| .
